Overview

Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This study investigates the safety, tolerability, and PK profile of finafloxacin as a novel fluoroquinolone and a potential therapeutic agent for lower respiratory infections such as bacterial pneumonia. A comparison of the PK profile of finafloxacin in plasma and lung ELF using different bronchoscopic ELF sampling techniques (BMS and BAL) is conducted.
Phase:
Phase 1
Details
Lead Sponsor:
MerLion Pharmaceuticals GmbH
Treatments:
Finafloxacin
Fluoroquinolones